What have we learned from clinical neuroprotective trials?
- 1 September 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 57 (suppl_2) , S45-S47
- https://doi.org/10.1212/wnl.57.suppl_2.s45
Abstract
Although no neuroprotective agent is yet available for acute stroke patients, the information we have gleaned from clinical neuroprotective trials is incredibly valuable. We know that these agents are biologically active, potentially safe, and likely to have a primary role in the acute treatment of the stroke patient. The ischemic cascade has been attacked from a myriad of directions, and we now appreciate some of the advantages and limitations of preclinical models. We can use this knowledge to design more effective trials in the future.Keywords
This publication has 7 references indexed in Scilit:
- Early stroke treatment associated with better outcomeNeurology, 2000
- A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic windowProceedings of the National Academy of Sciences, 1999
- Measuring quality of life in a way that is meaningful to stroke patientsNeurology, 1999
- The Stroke Impact Scale Version 2.0Stroke, 1999
- Termination of Acute Stroke Studies Involving Selfotel TreatmentThe Lancet, 1997
- MRI and Brainstem Auditory Evoked Potential Evidence of Eighth Cranial Nerve Involvement in Multiple SclerosisNeurology, 1997
- Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome After Embolic StrokeArchives of Neurology, 1991